Liquid Biopsy Firm Freenome Finds a Way to the Public Markets via $330M SPAC Merger
Freenome’s SPAC merger agreement comes as the liquid biopsy developer prepares for potential 2026 commercialization of SimpleScreen, a colorectal cancer test currently under FDA review. If approved, the Freenome blood test would compete against Guardant Health’s liquid biopsy, Shield. The post Liquid Biopsy Firm Freenome Finds a Way to the Public Markets via $330M SPAC…